Rapid Micro Biosystems (RPID) AI Stock Analysis

• Market Cap: $181.28M
• Dividend Yield: N/A
• Average Volume (3M): 107.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: 16.63%
• EPS Growth: 10.43%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.26
• Shares Outstanding: 39,823,025
• 10 Day Avg. Volume: 82,174
• 30 Day Avg. Volume: 107,298
• PEG Ratio: 0.07
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 23.72
• Enterprise Value/Ebitda: -3.21
• 1Y Price Target: $8.00
• Price Target Upside: 95.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.99
• Revenue Forecast (FY): $32.08M

• Rating: 56 Neutral
• Price Target: $4.50 ▲(10.02% Upside)

Rapid Micro Biosystems' stock score is driven by strong revenue growth and positive technical indicators. However, ongoing profitability challenges and a negative valuation score due to losses weigh heavily on the overall score. The earnings call provided some optimism with future growth prospects, but immediate financial concerns remain.

Positive Factors

Revenue Growth

Consistent revenue growth over multiple quarters indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Recurring Revenue Model

A robust recurring revenue model provides financial stability and predictability, enhancing the company's ability to invest in future growth.

Strategic Partnership

The partnership with MilliporeSigma aims to lower costs and improve margins, potentially enhancing competitive positioning and profitability.

Negative Factors

Profitability Challenges

Ongoing net losses and negative margins highlight profitability challenges, which could hinder financial flexibility and long-term sustainability.

Increased Leverage

Higher leverage can strain cash flow and limit the company's ability to invest in growth opportunities, posing a risk to financial health.

Negative Operating Cash Flow

Negative operating cash flow suggests operational inefficiencies, which may affect the company's ability to sustain operations and invest in growth.

Rapid Micro Biosystems Business Overview & Revenue Model

Company Description

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

How the Company Makes Money

Rapid Micro Biosystems generates revenue through the sale of its Growth Direct System and related consumables, including proprietary growth media and software. The company operates on a recurring revenue model, benefiting from ongoing sales of consumables and maintenance services. Additionally, RPID partners with various pharmaceutical and biotech companies to provide customized solutions, which can lead to lucrative long-term contracts. The expansion of its customer base and the growing demand for rapid microbial testing in regulated industries contribute significantly to its earnings.

Rapid Micro Biosystems Financial Statement Overview

Summary

Rapid Micro Biosystems shows strong revenue growth but faces significant profitability and cash flow challenges. The increase in leverage and negative net income highlight the need for improved cost management and operational efficiency.

Income Statement

Rapid Micro Biosystems shows a significant revenue growth rate of 77.3% in the TTM, indicating strong top-line expansion. However, the company struggles with profitability, evidenced by negative margins across the board, including a net profit margin of -145.11% and an EBIT margin of -109.20%. The gross profit margin has improved to 24.18% in the TTM from negative figures in previous years, but the overall profitability remains a concern.

Balance Sheet

The company's debt-to-equity ratio has increased to 0.54 in the TTM from lower levels in previous years, indicating a rise in leverage. The return on equity remains negative at -73.91%, reflecting ongoing losses. However, the equity ratio is relatively stable, suggesting a solid equity base compared to total assets.

Cash Flow

The cash flow statement reveals a positive free cash flow growth rate of 78.6% in the TTM, but the operating cash flow remains negative. The operating cash flow to net income ratio is -2.25, indicating cash flow challenges. Despite these issues, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.52M	28.05M	22.52M	17.13M	23.23M	16.08M
Gross Profit	5.61M	-109.00K	-5.49M	-8.54M	-7.74M	-8.07M
EBITDA	-41.49M	-46.56M	-53.46M	-60.38M	-45.70M	-32.00M
Net Income	-44.29M	-46.89M	-52.47M	-60.81M	-73.52M	-37.08M
Balance Sheet
Total Assets	84.41M	98.17M	143.45M	190.65M	241.17M	70.00M
Cash, Cash Equivalents and Short-Term Investments	41.25M	50.73M	92.05M	108.65M	193.50M	45.08M
Total Debt	24.11M	6.17M	7.35M	7.97M	0.00	24.81M
Total Liabilities	40.08M	22.82M	25.46M	26.48M	20.19M	45.18M
Stockholders Equity	44.33M	75.35M	117.99M	164.17M	220.98M	24.82M
Cash Flow
Free Cash Flow	-38.58M	-45.52M	-46.93M	-65.29M	-58.18M	-31.69M
Operating Cash Flow	-37.73M	-44.15M	-45.08M	-58.55M	-54.96M	-31.00M
Investing Cash Flow	15.30M	36.66M	42.15M	-93.47M	-13.29M	-15.67M
Financing Cash Flow	19.32M	203.00K	149.00K	693.00K	216.75M	64.23M

Rapid Micro Biosystems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Positive. The current price of 4.09 is above the 20-day moving average (MA) of 3.92, above the 50-day MA of 3.47, and above the 200-day MA of 3.09, indicating a bullish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 56.06 is Neutral, neither overbought nor oversold. The STOCH value of 29.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPID.

Rapid Micro Biosystems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPID	56 Neutral	$181.28M	―	-68.83%	―	16.63%	10.43%
SGHT	56 Neutral	$260.79M	-5.19	-57.91%	―	-4.39%	11.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	48 Neutral	$96.28M	-1.97	-94.03%	―	-20.10%	7.87%
LUNG	44 Neutral	$70.08M	-1.20	-73.73%	―	15.59%	4.13%
LUCD	44 Neutral	$139.06M	―	-331.24%	―	5.01%	20.76%
LNSR	38 Underperform	$122.67M	―	-422.35%	―	21.02%	-200.88%

Rapid Micro Biosystems Corporate Events

Rapid Micro Biosystems’ Earnings Call Highlights Growth Amid Challenges

The recent earnings call for Rapid Micro Biosystems, Inc. Class A revealed a mixed sentiment. While the company celebrated a significant multi-system order and robust growth in consumables revenue, challenges such as negative product margins and a net loss were also acknowledged. The collaboration with MilliporeSigma is expected to enhance cost efficiencies and drive future growth, reflecting a cautiously optimistic outlook.

Rapid Micro Biosystems Reports Q3 Growth and Raises Guidance

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company that provides automation solutions for efficient manufacturing and safe release of healthcare products, primarily operating in the pharmaceutical sector. In its third quarter of 2025, the company reported a total revenue of $7.8 million, marking a 3% increase from the previous year, with a notable 32% rise in recurring revenue driven by record consumable sales. The company also announced a significant multi-system order from a top global biopharma customer, which is expected to enhance its growth trajectory. Key financial highlights include a gross margin improvement to 9%, a reduction in operating expenses by 5%, and a net loss of $11.5 million, consistent with the previous year. Looking ahead, Rapid Micro Biosystems has raised its full-year revenue guidance to at least $33 million, anticipating substantial contributions from its recent customer order and continued adoption of its Growth Direct platform.

Rapid Micro Biosystems Earnings Call: Growth Amid Challenges

The recent earnings call of Rapid Micro Biosystems, Inc. Class A painted a mixed picture of the company’s current financial health and future prospects. While the call highlighted significant revenue growth and strategic advancements, including a new loan facility and progress in partnerships, it also acknowledged challenges with product margins and ongoing market uncertainties affecting system placements.